ReviewJournal of hematology & oncology2016
Current status and perspectives in translational biomarker research for PD-1/PD-L1 immune checkpoint blockade therapy.
Review in Journal of hematology & oncology, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 5 registered trials, which are not on this map. Cited by 196 papers, 5 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Toripalimab Plus Lenvatinib as Second-line Treatment in Advanced Biliary Tract Cancers: a Single-arm, Non-randomized, Single-center Clinical Trial and Biomarker Study
Relationship Between Histopathological Features, Mutation Status, 18F-FDG PET/CT Radiomic Imaging Parameters as Well as Clinical Outcome in Patients With Treatment-naïve Non-small Cell Lung Cancer
Lenvatinib Combined Toripalimab in Advanced Hepatocellular Carcinoma: a Single-center, Single-arm, Non-randomized Clinical Study
A Single-arm, Non-randomized, Single-center Study to Evaluate Lenvatinib in Combination With Camrelizumab as First-Line Therapy in Patients With Advanced Hepatocellular Carcinoma
Hepatic Arterial Infusion Chemotherapy Combine With Lenvatinib and PD-1 Inhibitors for Advanced Hepatocellular Carcinoma With Portal Vein Tumor Thrombosis.
Who cites it
196 citing papers in PubMed, 5 syntheses or guidelines pooled it.
- Prognostic significance of programmed cell death-ligand 1 expression on circulating tumor cells in various cancers: A systematic review and meta-analysis.Cancer medicine · 2021Pooled it
- Treatment-Related Serious Adverse Events of Immune Checkpoint Inhibitors in Clinical Trials: A Systematic Review.Frontiers in oncology · 2021Pooled it
- Adverse Events of Concurrent Immune Checkpoint Inhibitors and Antiangiogenic Agents: A Systematic Review.Frontiers in pharmacology · 2019Pooled it
- PD-L1 diagnostic tests: a systematic literature review of scoring algorithms and test-validation metrics.Diagnostic pathology · 2018Pooled it
- PD-L1 expression in lung cancer and its correlation with driver mutations: a meta-analysis.Scientific reports · 2017Pooled it
- Prediction of Disease Progression to Upfront Pembrolizumab Monotherapy in Advanced Non-Small-Cell Lung Cancer with High PD-L1 Expression Using Baseline CT Disease Quantification and Smoking Pack Years.Current oncology (Toronto, Ont.) · 2023Trial
- Randomized Phase 2 Trial of Pharmacodynamic Separation of Pemetrexed and Intercalated Erlotinib Versus Pemetrexed Alone for Advanced Nonsquamous, Non-small-cell Lung Cancer.Clinical lung cancer · 2017Trial
- Early antibiotic exposure reduces progression-free survival in unresectable hepatocellular carcinoma patients treated with TACE plus TKI and ICI therapy: a propensity score-matched analysis.BMC gastroenterology · 2026Article
- LncRNA SOX21-AS1 is associated with poor prognosis and immunomodulation in glioblastoma.Translational cancer research · 2026Article
- The cGAS-STING pathway in cancer: friend or foe.Cell death & disease · 2026Review
- Multifunctional Graphene Oxide Quantum Dot Nanoformulation with Key Immunomodulation for Effective Anticancer Therapy in Mice Model.International journal of nanomedicine · 2026Article
- Training on PD-L1 scoring in non-small cell lung cancer with high intra- and inter-reader agreement: results of a worldwide microscopic/digital image-based training of 751 pathologists.British journal of biomedical science · 2026Article
- Lypd6b depletion promotes CD8Nature communications · 2025Article
- Predictive value of immunomodulatory-related genes for the prognosis of lung adenocarcinoma based on bioinformatics analysis.Discover oncology · 2025Article
- Neuromuscular complications associated with cancer immunotherapy.Journal of the National Cancer Center · 2025Review
- Immune checkpoint inhibitors for advanced oesophageal cancer treated with surgery, radiotherapy or chemotherapy.The Cochrane database of systematic reviews · 2025Article
- Clinical efficacy and safety of sintilimab plus oral vinorelbine as first-line treatment for newly diagnosed stage IIIB-IV nonsmall cell lung cancer patients with performance status 2 or age ≥75 years.Anti-cancer drugs · 2025Article
- Review
- Potentiating intratumoral therapy with immune checkpoint inhibitors: shifting the paradigm of multimodality therapeutics.Immuno-oncology technology · 2025Review
- Imaging PD-L1 in the brain-Journey from the lab to the clinic.Neuro-oncology · 2025Article
136 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
Modulating immune inhibitory pathways has been a major recent breakthrough in cancer treatment. Checkpoint blockade antibodies targeting cytotoxic T-lymphocyte antigen 4 (CTLA-4) and programed cell-death protein 1 (PD-1) have demonstrated acceptable toxicity, promising clinical responses, durable disease control, and improved survival in some patients with advanced melanoma, non-small cell lung cancer (NSCLC), and other tumor types. About 20 % of advanced NSCLC patients and 30 % of advanced melanoma patients experience tumor responses from checkpoint blockade monotherapy, with better clinical responses seen with the combination of anti-PD-1 and anti-CTLA-4 antibodies. Given the power of these new therapies, it is important to understand the complex and dynamic nature of host immune responses and the regulation of additional molecules in the tumor microenvironment and normal organs in response to the checkpoint blockade therapies. In this era of precision oncology, there remains a largely unmet need to identify the patients who are most likely to benefit from immunotherapy, to optimize the monitoring assays for tumor-specific immune responses, to develop strategies to improve clinical efficacy, and to identify biomarkers so that immune-related adverse events can be avoided. At this time, PD-L1 immunohistochemistry (IHC) staining using 22C3 antibody is the only FDA-approved companion diagnostic for patients with NSCLC-treated pembrolizumab, but more are expected to come to market. We here summarize the current knowledge, clinical efficacy, potential immune biomarkers, and associated assays for immune checkpoint blockade therapies in advanced solid tumors.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.